DNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback